Literature DB >> 30600427

Assessment of direct oral anticoagulant assay use in clinical practice.

Tina M Gu1, David A Garcia2, Daniel E Sabath3.   

Abstract

There are no clear and consistent guidelines on how to utilize DOAC assays, and reports on the use of DOAC levels in clinical practice is limited. The objective of this study was to analyze why DOAC levels are ordered, how the results affect clinical decision-making, and to determine if DOAC assays are utilized appropriately. This was a retrospective chart review study analyzing 150 dabigatran, rivaroxaban, and apixaban levels performed at a single institution. The majority of DOAC assays were ordered in situations or special patient populations where confirming absence or detecting presence of drug may be useful. The most common indication for ordering assays was prior to an invasive procedure. Most DOAC levels were timed appropriately but peak levels were most likely to be incorrectly ordered. Clinical decisions following level results depended on indication for ordering and were most commonly used to determine whether or not to proceed with an invasive procedure. The results of our study suggest while DOAC assays are generally ordered for useful indications, there is still a lack of understanding of when levels should be drawn and how to interpret DOAC assay results.

Entities:  

Keywords:  Anticoagulant agents; Apixaban; Dabigatran; Drug monitoring; Rivaroxaban

Mesh:

Substances:

Year:  2019        PMID: 30600427     DOI: 10.1007/s11239-018-1793-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  3 in total

Review 1.  Laboratory Monitoring of Direct Oral Anticoagulants (DOACs).

Authors:  Claire Dunois
Journal:  Biomedicines       Date:  2021-04-21

2.  Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system.

Authors:  Nicholas Jakowenko; Steffany Nguyen; Melanie Ruegger; Ashley Dinh; Eric Salazar; Kevin R Donahue
Journal:  Thromb Res       Date:  2020-09-06       Impact factor: 3.944

Review 3.  Proximal femur fractures in patients taking anti-coagulants: has anything changed?

Authors:  Marilena Giannoudi; Peter V Giannoudis
Journal:  EFORT Open Rev       Date:  2022-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.